In an effort to combat cancer, Merus N.V. - a clinical-stage immuno-oncology company based in the Netherlands - is developing a pipeline of promising antibody therapeutics. Among its candidates is Zenocutuzumab (MCLA-128), currently in phase 2 clinical trials as a potential treatment option for metastatic breast cancer and castration-resistant prostate cancer. MCLA-128 is also undergoing phase 1/2 clinical trials for the treatment of solid tumors with Neuregulin 1. Other candidates include MCLA-158, which is in phase I clinical trial for the treatment of solid tumors, MCLA-145 in phase 1 clinical trials for the treatment of solid tumors, MCLA-129 in phase 1/2 clinical trials for the treatment of advanced non-small cell lung cancer and other tumors, and ONO-4685 in a Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. Merus N.V. has also partnered with Betta Pharmaceuticals Co. Ltd and Incyte Corporation for the research and development of bispecific antibody candidates, including MCLA-129 and MCLA-145, respectively. The company, founded in 2003, is headquartered in Utrecht, the Netherlands.